These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32488048)

  • 1. Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers.
    Marx A; Schumann A; Höflmayer D; Bady E; Hube-Magg C; Möller K; Tsourlakis MC; Steurer S; Büscheck F; Eichenauer T; Clauditz TS; Graefen M; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Haese A; Schlomm T; Bernreuther C; Lebok P; Polonski A
    Sci Rep; 2020 Jun; 10(1):8916. PubMed ID: 32488048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
    Eichenauer T; Federlein F; Möller K; Chirico V; Kind S; Lennartz M; Lutz F; Hube-Magg C; Höflmayer D; Fisch M; Huland H; Heinzer H; Graefen M; Haese A; Schroeder C; Lebok P; Minner S; Simon R; Sauter G; Schlomm T; Wilczak W; Steurer S; Luebke AM
    Pathology; 2020 Jun; 52(4):421-430. PubMed ID: 32317175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
    Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
    Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen attenuates the inactivating phospho-Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity.
    Cinar B; Al-Mathkour MM; Khan SA; Moreno CS
    J Biol Chem; 2020 Jun; 295(25):8550-8559. PubMed ID: 32376689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
    Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
    J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
    Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
    Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A
    Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
    BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.
    Büscheck F; Zub M; Heumann A; Hube-Magg C; Simon R; Lang DS; Höflmayer D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Sauter G; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Clauditz TS; Burandt E; Wilczak W; Steurer S; Minner S
    Tumour Biol; 2019 Jul; 41(7):1010428318824815. PubMed ID: 31296150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer.
    Steurer S; Hager B; Büscheck F; Höflmayer D; Tsourlakis MC; Minner S; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Izbicki JR; Burandt E; Sauter G; Fraune C; Weidemann S; Schlomm T; Heinzer H; Haese A; Graefen M; Huland H; Heumann A
    Aging (Albany NY); 2019 Sep; 11(18):7859-7879. PubMed ID: 31557128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
    Zabalza CV; Adam M; Burdelski C; Wilczak W; Wittmer C; Kraft S; Krech T; Steurer S; Koop C; Hube-Magg C; Graefen M; Heinzer H; Minner S; Simon R; Sauter G; Schlomm T; Tsourlakis MC
    Oncotarget; 2015 May; 6(14):12822-34. PubMed ID: 25825985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
    Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
    Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
    Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer.
    Latz S; Umbach T; Goltz D; Kristiansen G; Müller SC; Ellinger J
    Urol Int; 2016; 96(1):39-45. PubMed ID: 26287745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
    Matsuda Y; Narita S; Nara T; Mingguo H; Sato H; Koizumi A; Kanda S; Numakura K; Saito M; Inoue T; Hiroshima Y; Nanjo H; Satoh S; Tsuchiya N; Habuchi T
    BMC Cancer; 2020 Apr; 20(1):302. PubMed ID: 32293349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
    Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
    Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.